Johnson and Johnson Gets CDSCO Panel Nod For Additional Indication of Daratumumab to Treat Light chain AL amyloidosis

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-05-25 12:30 GMT | Update On 2024-05-25 12:30 GMT

New Delhi: Granting local clinical trial waiver, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved Johnson and Johnson's anticancer drug Daratumumab solution for Injection 1800 mg (120 mg/ml) for an additional indication for the treatment of Light chain (AL) amyloidosis in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic AL amyloidosis.

This came after Johnson and Johnson presented the proposal for approval of additional indication i.e, for the treatment of Light chain (AL) amyloidosis in combination with cyclophosphamide, bortezomib, and dexamethasone for the treatment of adult patients with newly diagnosed systemic AL amyloidosis along with a request for local clinical trial waiver.

The committee noted that the treatment of Light chain (AL) amyloidosis comes under the orphan drug category, and the applied indication is approved in the US, EU, Canada, Brazil, Switzerland, the U.K., and China.

Amyloidosis is a disorder of protein misfolding and metabolism in which insoluble fibrils are deposited in various tissues, causing organ dysfunction and eventually death.

Primary or light chain (AL) amyloidosis, the most common type of systemic amyloidosis, occurs when the free light chains normally associated with immunoglobulins are produced in excess by clonal or frankly malignant plasma cells. Although AL amyloidosis is not considered a cancer, it shares some similar characteristics and treatments with multiple myeloma.

Daratumumab is a CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma and light chain amyloidosis. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found in some types of immune cells and tumor cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill tumor cells.

Daratumumab binds to CD38, causing cells to apoptosis via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, inhibition of mitochondrial transfer, or antibody-dependent cellular phagocytosis.

At the recent SEC meeting held for Oncology on 15th May 2024, the expert panel reviewed the proposal presented by Johnson and Johnson for approval of additional indication of Daratumumab solution for Injection 1800 mg (120 mg/ml) for the treatment of Light chain (AL) amyloidosis in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic AL amyloidosis along with a request for local clinical trial waiver.

The committee observed that the treatment of Light chain (AL) amyloidosis comes under the orphan drug category. Furthermore, the expert panel highlighted that the applied indication for the treatment of Light Chain (AL) Amyloidosis is approved in the US, EU, Canada, Brazil, Switzerland, the UK, and China.

After detailed deliberation, the committee recommended approval of the proposed additional indication with a waiver of a local clinical trial with the condition to conduct the Phase IV clinical trial.

Accordingly, the expert panel suggested that the firm should submit the Phase IV clinical trial protocol to CDSCO within 3 months for SEC deliberation.

Also Read:Discontinue Olaparib Tablets Marketing For Specific Cancers: CDSCO

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Johnson and Johnson Gets CDSCO Panel Nod For Additional Indication of Daratumumab to Treat Light chain AL amyloidosis

Similar News

Sanofi Rilzabrutinib earns orphan designation in EU for IgG4 related disease

Novo Nordisk Launches Wegovy in South Africa, Ramping Up Obesity Drug Battle with Eli Lilly

Lupin to Conduct BE Study for Synthetic Semaglutide Tablets in 3 Strengths

Sun Pharma Gets CDSCO Panel Nod for Active PMS of Fexuprazan Hydrochloride Tablets

Chemists' Body Warns of 55% Rise in Drug Abuse, Calls for Ban on 10-Minute Prescription Drug Delivery

Cohance Lifesciences announces USD 10 mn investment in cGMP Bioconjugation Suite at NJ Bio

Bayer, Kumquat Biosciences ink pact to develop, commercialize KRAS G12D inhibitor

Setback to Torrent: CDSCO Panel Rejects Phase III Waiver Plea for Prucalopride Over Safety Data Gaps